Virumeter for rapid detection of covid19 and other pathogens

Abstract

Embodiments may include a virumeter for rapid detection of COVID-19 infection and assessment of immunity to the virus. For example, a device for detecting primary antibodies to a pathogen or the pathogen may comprise a cartridge to receive a test sample from the person, the cartridge comprising at least one chamber to receive the test sample, first apparatus to mix at least one first reagent reactive to presence of the primary antibodies to the pathogen or the pathogen, second apparatus to mix at least one second reagent including a fluorescent compound with the test sample reactive to presence of the at least one first reagent having reacted to presence of the primary antibodies to the pathogen or the pathogen, and circuitry to determine presence of primary antibodies to the pathogen or the pathogen by detecting reaction of the second reagent by determining fluorescence of the fluorescent compound.

1 . A device for detecting primary antibodies to a pathogen or the pathogen in a person comprising:
 a cartridge configured to receive a test sample from the person, wherein the test sample is saliva, the cartridge comprising at least one chamber configured to receive the test sample;   a first reagent reactive to presence of primary antibodies to the pathogen or the pathogen, wherein the pathogen is SARS-CoV-2;   first apparatus configured to mix at least the first reagent reactive to presence of the primary antibodies to the pathogen or the pathogen with the test sample;   a second reagent including a fluorescent compound reactive to presence of the at least one first reagent having reacted to presence of the primary antibodies to the pathogen or the pathogen;   second apparatus configured to mix at least one second reagent with the test sample mixed with the first reagent; and   circuitry configured to determine presence of primary antibodies to the pathogen or the pathogen by detecting reaction of the second reagent by determining fluorescence of the fluorescent compound.   
     
     
         2 . The device of  claim 1 , wherein the first apparatus further comprises a plurality of magnetic particles upon which at least one antigen to primary antibodies to the pathogen has been immobilized, wherein the at least one first reagent comprises the at least one antigen to primary antibodies that has been immobilized on the plurality of magnetic particles, wherein the antigen is SARS-CoV-2 S1 protein. 
     
     
         3 . The device of  claim 2 , wherein the first apparatus further comprises apparatus configured to mix the plurality of magnetic particles with the test sample so as to cause the primary antibodies to the pathogen to attach to the antigen. 
     
     
         4 . The device of  claim 3 , wherein the second apparatus comprises apparatus configured to mix the magnetic particles having the primary antibodies to the pathogen to attached thereto with the at least one second reagent including a fluorescent compound. 
     
     
         5 . The device of  claim 4 , wherein the at least one second reagent including a fluorescent compound comprises at least one secondary antibody labeled with a fluorescent compound. 
     
     
         6 . The device of  claim 1 , wherein the circuitry configured to determine presence of primary antibodies to the pathogen or the pathogen by detecting reaction of the second reagent by determining fluorescence of the fluorescent compound comprises a fluorometer. 
     
     
         7 . The device of  claim 6 , wherein the circuitry configured to determine presence of primary antibodies to the pathogen or the pathogen by detecting reaction of the second reagent by determining fluorescence of the fluorescent compound comprises:
 a light source configured to excite the fluorescent compound with a of light, and   an optical sensor configured to detect an emitted spectrum of light from the excited fluorescent compound.   
     
     
         8 . The device of  claim 1 , further comprising display circuitry configured to display an indication of presence or absence of primary antibodies to the pathogen. 
     
     
         9 - 11 . (canceled) 
     
     
         12 . The device of  claim 5 , wherein the secondary antibodies comprise IgA, IgM, and IgG and each of IgA, IgM, and IgG is labeled with a fluorescent compound having a different light emission spectrum. 
     
     
         13 - 22 . (canceled)